IMMUTEP

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system... Immutep is a leading biotechnology company focused on developing effective autoimmune and cancer immunotherapy treatments such as Lag-3... Since those discoveries, Immutep has been a pioneer in developing therapeutics that are distinctly designed around the interplay of LAG-3 and MHC II to either stimulate or suppress the immune system to fight cancer or eradicate autoimmune diseases. Today, we have a diversified portfolio of cutting-edge immuno-oncology and targeted LAG-3 immunotherapy including three clinical stage candidates, one pre-clinical candidate, and one candidate that is early-stage.

Also known as: Immutep Australia Pty Ltd, Immutep GmbH, Immutep Limited, Immutep S.A.S.

Primary location: Sydney Australia